The CD300LD Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, designed for targeted disruption of the CD300LD gene. This pool of genetically heterogeneous knockout cells provides a robust loss-of-function model for studying CD300LD-mediated inhibitory signaling without the limitations of clonal variation.
The parental HeLa cell line is a well-characterized, adherent epithelial model originally isolated from a cervical carcinoma, and it harbors integrated human papillomavirus type 18 (HPV18) sequences. These immortalized cells are widely employed in cancer biology, signal transduction, and drug discovery research due to their ease of culture, genetic tractability, and established use in functional genomics.
CD300LD is an inhibitory immunoreceptor containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, upon engagement by unidentified endogenous ligands (possibly lipid mediators such as phosphatidylserine), undergoes phosphorylation by Src family kinases including Lyn and Fyn. This triggers recruitment and activation of SHP-1, SHP-2, and SHIP phosphatases, leading to dephosphorylation of proximal signaling molecules, attenuation of ITAM-mediated activation pathways, and suppression of downstream effectors such as PI3K/AKT and NF-??B, ultimately reducing calcium mobilization and pro-inflammatory cytokine production.
In the HeLa epithelial carcinoma context, CD300LD knockout enables dissection of the receptor??s intrinsic signaling properties and its potential contributions to tumor cell-intrinsic immune evasion or modulation of inflammatory responses. While CD300LD is predominantly studied in myeloid cells, ectopic expression or endogenous low-level expression in epithelial tumor lines can be investigated using this polyclonal knockout pool to assess impacts on cell proliferation, migration, or cytokine profiles, providing a versatile platform for immune checkpoint research.
Researchers can employ these cells in a variety of experimental workflows, including Western blotting to confirm CD300LD loss and monitor ITIM phosphorylation, flow cytometry to quantify surface receptor expression, co-immunoprecipitation to assess interactions with SHP-1 or SHP-2, and NF-??B luciferase reporter assays to evaluate downstream signaling. Additional applications include cytokine secretion profiling by ELISA for TNF-?? and IL-6, phospho-AKT analysis, and RNA sequencing to characterize global transcriptomic changes. For further details or to request a quotation, please contact Ascent Research.
